Comparison of desferrioxamine and NODAGA for the gallium-68 labeling of exendin-4

EJNMMI Radiopharmacy and Chemistry

Simon A. M. Kaeppeli¹  Martin Behe¹  Roger Schibli²  Thomas L. Mindt³ 

[1] 0000 0001 1090 7501, grid.5991.4, Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, OIPA/102, Forschungsstrasse 111, 5232, Villigen-PSI, Switzerland;0000 0001 1090 7501, grid.5991.4, Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, OIPA/102, Forschungsstrasse 111, 5232, Villigen-PSI, Switzerland;0000 0001 2156 2780, grid.5801.c, Department of Chemistry and Applied Biosciences, ETH Zurich, Vladimir-Prelog-Weg 4, 8093, Zurich, Switzerland;0000 0004 0520 9719, grid.411904.9, Ludwig Boltzmann Institute Applied Diagnostics, General Hospital Vienna (AKH), c/o Sekretariat Nuklearmedizin Währinger Gürtel 18-20, Vienna, Austria;0000 0000 9259 8492, grid.22937.3d, Department of Biomedical Imaging and Image Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria;

关键词: Exendin-4;    β-cells;    Insulinoma;    GLP-1R;    NODAGA;    DFO;   

DOI  :  10.1186/s41181-019-0060-9

来源: publisher

【 摘 要 】

IntroductionRadiolabeled exendin-4 (Ex4) derivatives are used to target the glucagon-like peptide-1 receptor (GLP-1R) for the clinical diagnosis of insulinomas, a rare type of neuroendocrine tumor. Gallium-68 is an ideal diagnostic nuclide for this application and a study evaluating an exendin-4-NODAGA conjugate is currently underway. However, in complexion with the chelator DFO, its in vivo stability has been a matter of dispute. The aim of this work was to directly compare [68Ga]Ga-Ex4NOD with [68Ga]Ga-Ex4DFO in vitro and in vivo.MethodsIn our approach, we directly compared N′-[5-(acetyl-hydroxy-amino)pentyl]-N-[5-[3-(5-aminopentyl-hydroxy-carbamoyl)propanoylamino]pentyl]-N-hydroxy-butane diamide (desferriox-amine B, DFO) and 2-(4,7-bis (carboxymethyl)-1,4,7-triazonan-1-yl) pentanedioic acid (NODAGA) conjugated to exendin-4 in vitro and in vivo. We radiolabeled the peptides with gallium-68, followed by HPLC quality control. In vitro characterization was performed in CHL cells overexpressing the GLP-1R and in vivo studies were conducted with CD1 nu/nu mice carrying tumors derived from these cells.ResultsWe found that both peptides could be radiolabeled with a molar activity of about 9.33 MBq/nmol without further purification. They internalized equally well into GLP-1R-expressing cells and their IC50 was similar with 15.6 ± 7.8 nM and 18.4 ± 3.0 nM for [natGa]Ga-Ex4NOD and [natGa]Ga-Ex4DFO, respectively. In vivo, [68Ga]Ga-Ex4NOD accumulated more in all tissue, while [68Ga]Ga-Ex4DFO exhibited a more favorable target-to-kidney ratio.Conclusion and relevanceDFO is a suitable chelator for the radiolabeling of exendin-4 derivatives with gallium-68 for in vitro and preclinical in vivo studies. DFO performed better in vivo due to its significantly lower kidney accumulation (p < 0.0001). It was also found to be stable in vivo in mice, contrary to earlier reports. Based on our results, the DFO chelating system in combination with exendin-4 would be an interesting option for clinical imaging of insulinomas.

【 授权许可】

CC BY